List of Tables
    Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Opportunities & Trends in Global Market
    Table 2. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers in Global Market
    Table 3. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints in Global Market
    Table 4. Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC in Global Market
    Table 5. Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Targeted Drug EGFR RTK Inhibitors for NSCLC Product Type
    Table 9. List of Global Tier 1 Targeted Drug EGFR RTK Inhibitors for NSCLC Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Targeted Drug EGFR RTK Inhibitors for NSCLC Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2023-2028
    Table 30. Beta Pharma Corporate Summary
    Table 31. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 32. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 33. AstraZeneca Corporate Summary
    Table 34. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 35. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 36. Natco Pharma Corporate Summary
    Table 37. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 38. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 39. Qilu Pharmaceutical Corporate Summary
    Table 40. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 41. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 42. Genentech (Roche Group) Corporate Summary
    Table 43. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 44. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 45. Mylan Corporate Summary
    Table 46. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 47. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 48. Teva Corporate Summary
    Table 49. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 50. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 51. OSI Pharmaceuticals Corporate Summary
    Table 52. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 53. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 54. Glenmark Pharmaceuticals Corporate Summary
    Table 55. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 56. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 57. Beacon Pharmaceuticals Corporate Summary
    Table 58. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 59. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 60. Boehringer Ingelheim Corporate Summary
    Table 61. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 62. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 63. Pfizer Corporate Summary
    Table 64. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 65. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 66. ARIAD Pharmaceuticals (Takeda) Corporate Summary
    Table 67. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 68. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 69. Genvio Pharma Limited Corporate Summary
    Table 70. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 71. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 72. Drug International Limted Corporate Summary
    Table 73. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 74. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 75. Everest Pharmaceuticals Corporate Summary
    Table 76. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 77. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 78. Incepta Pharmaceuticals Limited Corporate Summary
    Table 79. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 80. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 81. Cipla Pharma Corporate Summary
    Table 82. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 83. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 84. Dr Reddy's Laboratories Corporate Summary
    Table 85. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 86. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 87. Zydus Cadila Corporate Summary
    Table 88. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 89. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 90. Hetero Drugs Corporate Summary
    Table 91. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 92. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 93. Intas Pharmaceuticals Corporate Summary
    Table 94. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 95. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 96. Alkem Laboratories Corporate Summary
    Table 97. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 98. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 99. RPG Life Sciences Corporate Summary
    Table 100. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 101. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
    Table 102. Fresenius Kabi India Corporate Summary
    Table 103. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offerings
    Table 104. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type in 2021
    Figure 2. Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application in 2021
    Figure 3. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2021
    Figure 8. By Type - Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 12. US Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 16. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 17. France Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 24. China Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 28. India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 30. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share, 2017-2028
    Figure 33. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, (US$, Mn), 2017-2028
    Figure 37. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 47. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 48. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 49. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 50. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 51. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 52. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 53. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 54. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 55. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 56. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 57. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 58. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 59. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 60. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 61. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Year Over Year Growth (US$, Mn) & (2017-2022)